{"groups":[{"description":"Participants undergo ≤3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.3 mg/m\\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\\^2 IV on Days 1, 4, 8, and 11).","id":"FG000","title":"Vorinostat + Bortezomib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Status unknown"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Adult male and female participants with relapsed and/or refractory multiple myeloma (MM) were enrolled at study sites in Japan."}